<DOC>
	<DOC>NCT01863758</DOC>
	<brief_summary>To compare the number of breakthrough bleeds under tailored prophylaxis with human cell line recombinant factor FVIII (Human-cl rhFVIII) with the historical bleeding rate from patients who received Human-cl rhFVIII as on demand treatment.</brief_summary>
	<brief_title>Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe Haemophilia A (FVIII:C &lt;1%) according to medical history Male patients &gt;= 18 year Previous treatment with a FVIII concentrate (regular prophylaxis with good compliance or ondemand treatment) for at least 150 Exposure Days (EDs) Good documentation regarding dosing and bleeding frequency in the 6 months preceding study start Immunocompetence (CD4+ count &gt; 200/microliter) HIVnegative, if positive, viral load &lt;200 particles/microliter or &lt; 400,000 copies/mL Any coagulation disorder other than Haemophilia A Present or past FVIII inhibitor activity (&gt; 0.6 BU) Severe liver or kidney disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>